Clinical trials: Organ Preservation
Renal Transplant, Kidney Transplant
Evaluation of Thiosulfate Enhanced Organ Preservation Solution in Kidney Transplantation
End-stage renal disease (ESRD) is a significant clinical problem for which dialysis or transplantation is required. The current need for kidneys for transplantation vastly exceeds the supply available from live donors…
- Trial name
- NCT06288152
- Testing
- Sodium Thiosulfate
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Alp Sener
Liver Preservation
Trial of the TransMedics Organ Care System™ Liver For Preserving and Assessing Donor Livers for Transplantation
A prospective, single-center controlled trial to evaluate the safety and performance of the portable Organ Care System (OCS) Liver for preservation and assessment of donor livers for transplantation.
- Trial name
- REVIVE (NCT02449694)
- Testing
- OCS Liver
- Where
- United Kingdom
- Volunteers
- 25 people
- Sponsor
- TransMedics
Rectal Cancer
Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer
Patients diagnosed with locally advanced very low rectal cancer were chosen to participate in a comprehensive neoadjuvant therapy (TNT) protocol.
- Trial name
- TRACE-LE (NCT05969847)
- Testing
- split-course hypofraction radiotherapy, CAPOX, Envafolimab
- Where
- China
- Volunteers
- 72 people
- Sponsor
- 池畔
Breast Cancer, Hormone Changes
Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as triptorelin, may protect normal ovarian cells from the side effects of…
- Conditions
- Breast Cancer, Hormone Changes, Drug Toxicity
- Trial name
- NCT00090844
- Testing
- triptorelin
- Where
- 9 sites in United States
- Volunteers
- 49 people
- Sponsor
- University of South Florida
Rectal Cancer
Application of PD-1 Monoclonal Antibody in Combination With IL-2 and CapeOX in Organ Preservation Therapy for Ultra-Low Localized Advanced Rectal Cancer
The objective is to evaluate whether the neoadjuvant combination of PD-1 inhibitor tislelizumab and interleukin-2 (IL-2) can significantly enhance the complete response rate (cCR + local excision pCR) and organ preservation rate…
- Trial name
- NCT06504875
- Testing
- Tislelizumab, Interleukin-2, Capecitabine
- Volunteers
- 23 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Rectal Cancer
Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer
The purpose of the research is to evaluate whether both chemotherapy and radiotherapy can lead to higher rates of clinical complete response leading to organ preservation in human subjects with cancer.
- Trial name
- NCT04380337
- Testing
- FOLFOXIRI, FOLFOX regimen, XELOX
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Stanford University
Organ Preservation Solutions
Peri-operative rATG-perfusion of Solid Transplants
The increasing demand for organ transplantation and the shortage of available organs limit the success of organ transplantation programs.
- Trial name
- ATG-perfusion (NCT03377283)
- Testing
- organ perfusion with rabbit anti-thymocyte globulin (rATG), organ perfusion with saline
- Volunteers
- 80 people
- Sponsor
- Medical University Innsbruck
Rectal Cancer
A Multicenter Single-arm P2 to Evaluate Safety and Efficacy of the Total Neoadjuvant Therapy for cT2 Rectal Cancer
A multicenter single-arm phase 2 study to evaluate safety and efficacy of the total neoadjuvant therapy of short course radiation therapy followed by neoadjuvant oxaliplatin/fluorouracil-based chemotherapy (CAPOX) for cT2 rectal…
- Trial name
- AMBITION (NCT05939661)
- Testing
- Radiation, Chemotherapy, Surgery
- Where
- 2 sites in Japan
- Volunteers
- 45 people
- Sponsor
- Osaka University
Rectum Cancer
Total Neoadjuvant Therapy Followed by 'Watch and Wait' Approach or Organ Preservation for Low-risk Rectal Cancer
Aim: To investigate the safety and efficacy of organ preservation (OP) with watch-and-wait strategy (W\&W) or local excision (LE) in MRI stratified low-risk rectal cancer treated by total neoadjuvant treatment.
- Trial name
- BJCC-R01 (NCT04405206)
- Testing
- Oxaliplatin, Capecitabine, intensity modulated radiotherapy
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Peking University Cancer Hospital & Institute
Locally Advanced Rectal Cancer (LARC), MSS (Microsatellite Stable)
SCRT Based iTNT vs. LCRT Based TNT for MSS Locally Advanced Rectal Cancer
In this prospective, multicentre, randomized phase III trial, 612 locally advanced rectal cancer (LARC, T3-4/N+M0) patients with at least one high-risk features (lower location (≤5cm), cT4, cN2, MRF+, EMVI+, TD+) will be…
- Trial name
- TORCH-STAR (NCT07551479)
- Testing
- short-course radiaotherapy, long-course chemoradiaothearpy, Capecitabine
- Where
- China
- Volunteers
- 612 people
- Sponsor
- Fudan University
Colorectal Cancer, Gastroesophageal Cancer
A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer
Background: People with colorectal cancer (CRC) or gastroesophageal cancer (GEC) must often have major surgery to remove tumors from the esophagus, stomach, colon, or rectum.
- Trial name
- NCT06410534
- Testing
- nivolumab, ipilimumab
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Gastroesophageal Adenocarcinoma
AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas
This study will test a new personalized treatment approach for patients with stomach or esophageal cancer. It will take place in two stages and aims to find the best combination of chemotherapy, immunotherapy, and targeted drugs…
- Trial name
- AACR-ADOPT-GEA (NCT07290985)
- Testing
- Tislelizumab, Leucovorin, Oxaliplatin
- Where
- 4 sites in United States, Canada
- Volunteers
- 242 people
- Sponsor
- American Association for Cancer Research
Rectal Tumour
Transanal Endoscopic Microsurgery (TEM) After Radiochemotherapy for Rectal Cancer
In the Netherlands approximately 2300 new patients are diagnosed with rectal cancer each year. Standard treatment for patients with a T2 or T3 rectal cancer consists of preoperative short course of radiotherapy followed by…
- Trial name
- CARTS (NCT01273051)
- Testing
- Capecitabine, radiotherapy, TME resection
- Where
- 13 sites in Netherlands
- Volunteers
- 55 people
- Sponsor
- Radboud University Medical Center
Heart Failure, Chronic Kidney Disease
Staged Kidney Transplantation During Combined Heart/Kidney Transplantation
The primary purpose of this study is to evaluate the safety and efficacy of ex vivo machine perfusion with staged implantation of kidney allografts during combined heart/kidney transplantation.
- Conditions
- Heart Failure, Chronic Kidney Disease, End-stage Kidney Disease
- Trial name
- NCT06877169
- Testing
- Planned delayed implantation of kidney allograft with ex vivo machine perfusion kidney preservation.
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cedars-Sinai Medical Center
Rectal Cancer
Tailored Operative or Non-operative Management for Low-risk Rectal Cancer After Intensive Neoadjuvant Treatment
This study is designed to test the efficacy of tailored operative or non-operative management (NOM) for MRI defined low-risk rectal cancer following neoadjuvant intensity modulated radiotherapy with concurrent capecitabine plus…
- Trial name
- NCT02860234
- Testing
- Oxaliplatin, Capecitabine, intensity modulated radiotherapy
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Peking University Cancer Hospital & Institute
Rectal Cancer
Organ Preservation in Early Rectal Cancer Patients
This is a single arm phase II study of neoadjuvant chemotherapy followed by local excision and post-operative chemoradiotherapy in patients with early stage, low rectal adenocarcinoma.
- Trial name
- NCT03548961
- Testing
- FOLFOX regimen
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Fox Chase Cancer Center
Gastrointestinal Cancers, Gastrointestinal Cancers - Stomach
Safety and Efficacy of NOM and OPFS Versus RO for dMMR/MSI-H or POLE-Mutated Gastrointestinal Cancers
Purpose: The purpose of this study is to evaluate the safety and efficacy of Non-Operative Management (NOM) and Organ Preservation First Strategy (OPFS) compared with Radical Operation (RO) in patients with deficient mismatch…
- Conditions
- Gastrointestinal Cancers, Gastrointestinal Cancers - Stomach, Gastrointestinal Cancers - Colorectal, Gastrointestinal Cancers - Anus
- Trial name
- NOR-MP (NCT07642323)
- Testing
- NOM/OPFS
- Volunteers
- 22 people
- Sponsor
- Peking University Cancer Hospital & Institute
Rectal Cancer
Organ Preservation First Strategy and Intentional Watch and Wait for MRI Defined Low-risk Rectal Cancer
The goal of this clinical trial is to test the safety and efficacy of local excision (LE) or non-operative management (NOM) in patients with MRI defined low-risk rectal cancer following neoadjuvant intensity modulated…
- Trial name
- NCT06209099
- Testing
- Nonoperative Management (NOM), Local Excision (LE), Total Mesorectal Excision (TME)
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Peking University Cancer Hospital & Institute
Liver Transplantation
Evaluation of Celsior® in Liver Transplant Preservation.
The aim of the study is to determine the efficacy and safety of a preservation solution in liver transplantation. Its efficacy will be compared to the efficacy of other currently used preservation solutions.
- Trial name
- NCT00151593
- Testing
- Celsior®
- Where
- 9 sites in France
- Volunteers
- 140 people
- Sponsor
- Rennes University Hospital
Gastrointestinal Malignancies
A Study of the Role of Circulating Tumor DNA in Predicting the Likelihood of Organ Preservation After Clinical Complete Response to Neoadjuvant Therapy for Rectal Cancer
In this research study, the investigators are looking to see if the circulating tumor DNA (genetic material), also known as ctDNA, in the blood will help them predict whether the participant's cancer will come back.
- Trial name
- NCT03749083
- Testing
- The Functional Assessment of Cancer Therapy- Colorectal
- Where
- 4 sites in United States
- Sponsor
- Massachusetts General Hospital